{"id":3117,"date":"2026-09-13T09:00:00","date_gmt":"2026-09-13T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3117"},"modified":"2026-09-14T20:29:31","modified_gmt":"2026-09-15T00:29:31","slug":"papillon-final-survival-analysis-requires-crossover-context","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3117","title":{"rendered":"PAPILLON Final Survival Analysis Requires Crossover Context"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Johnson & Johnson Innovative Medicine<\/p>\n

Event Type<\/strong><\/p>\n

Clinical Trial Results (Phase III, Final Overall Survival Analysis)<\/p>\n

Modality<\/strong><\/p>\n

Bispecific Antibody (EGFR x MET)<\/p>\n

Asset<\/strong><\/p>\n

Amivantamab (Rybrevant)<\/p>\n

Target<\/strong><\/p>\n

EGFR and MET<\/p>\n

Disease Area<\/strong><\/p>\n

EGFR Exon 20 Insertion-Positive Advanced Non-Small Cell Lung Cancer<\/p>\n

Summary<\/h4>\n

The final overall-survival analysis of PAPILLON reported median survival of 34.3 months with first-line amivantamab plus chemotherapy versus 27.9 months with chemotherapy alone, but the intent-to-treat comparison was not statistically significant (HR 0.87; P=0.307). A prespecified crossover-adjusted analysis favored the combination (HR 0.57; nominal P=0.003). The data are compatible with a treatment effect obscured by crossover, but they do not establish unadjusted randomized OS superiority.<\/p>\n

PAPILLON randomized 308 treatment-naive patients with advanced EGFR exon 20 insertion-positive NSCLC to amivantamab plus carboplatin-pemetrexed or chemotherapy alone. The trial previously demonstrated a 60% improvement in blinded-review PFS and supported global approvals. In the protocol-specified final OS analysis, median OS was 34.3 versus 27.9 months (HR 0.87; 95% CI 0.66\u20131.14; P=0.307). Patients assigned to chemotherapy could cross over to second-line amivantamab after confirmed progression.<\/p>\n

A prespecified analysis adjusting for crossover produced HR 0.57 (95% CI 0.39\u20130.82; nominal P=0.003). This is a model-dependent supportive analysis, not a replacement for the intent-to-treat estimate. Johnson & Johnson posted the detailed results on September 13 U.S. time and indexed them on its Innovative Medicine landing page on September 14.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that crossover materially diluted a true survival advantage. The median difference, adjusted HR, and established PFS benefit support that explanation. Its limitation is that adjustment relies on assumptions about post-progression treatment and patient comparability. A second interpretation is that the regimen improves disease control without proven OS superiority. The nonsignificant intent-to-treat result supports this stricter view; against it is the ethical crossover design, which makes an unconfounded survival contrast difficult. Both interpretations are plausible, so a categorical survival-superiority claim would be stronger than the randomized evidence supports.<\/p>\n

Company and Product Background<\/h4>\n

Johnson & Johnson develops amivantamab, marketed as Rybrevant, a bispecific antibody targeting EGFR and MET with receptor-blocking, receptor-degradation, and immune-effector mechanisms. EGFR exon 20 insertions create steric changes that reduce sensitivity to common EGFR tyrosine-kinase inhibitors. The regimen combines amivantamab with platinum-pemetrexed chemotherapy in the first-line metastatic setting.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • The final analysis supports treatment durability and strengthens payer and guideline discussions, but its evidentiary value depends on how decision-makers treat crossover adjustment.<\/li>\n
  • Upgrades if:<\/strong> multiple prespecified methods yield consistent effects, long-term PFS2 and patient-reported outcomes remain favorable, and safety-adjusted survival supports the combination.<\/li>\n
  • Downgrades if:<\/strong> adjusted results prove method-sensitive or post-progression imbalances unrelated to crossover explain the estimate.<\/li>\n
  • Falsified if:<\/strong> robust causal methods and external evidence converge on no meaningful survival effect.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    PAPILLON remains a positive PFS trial and a clinically important approved regimen. The final survival analysis is supportive but not definitive: the intent-to-treat endpoint missed significance, while the favorable crossover-adjusted estimate depends on modeling. Both facts should travel together.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 4\/5 \u2014 final survival evidence for an approved first-line targeted regimen. Importance:<\/strong> High \u2014 shapes how payers and guidelines weigh a regimen already in use. Confidence:<\/strong> High on facts, moderate-low on interpretation \u2014 canonical company disclosure and registered Phase III design are clear, but crossover adjustment is informative rather than definitive.<\/p>\n","protected":false},"excerpt":{"rendered":"

    The final overall-survival analysis of PAPILLON reported median survival of 34.3 months with first-line amivantamab plus chemotherapy versus 27.9 months with chemotherapy alone, but the intent-to-treat comparison was not statistically significant (HR 0.87; P=0.307)….<\/p>\n","protected":false},"author":1,"featured_media":3134,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[753,79,18],"class_list":["post-3117","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-amivantamab","tag-johnson-johnson","tag-non-small-cell-lung-cancer"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3117"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3117\/revisions"}],"predecessor-version":[{"id":3142,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3117\/revisions\/3142"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3134"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}